QIAGEN Partners with GENCURIX to Develop Multiplex Oncology Assays for QIAcuityDx Platform

Reuters

14小时前

QIAGEN Partners with GENCURIX to Develop Multiplex Oncology Assays for QIAcuityDx Platform

QIAGEN has announced a new partnership with GENCURIX, marking the launch of the QIAcuityDx Partnering Program. This collaboration focuses on developing oncology assays for the QIAcuityDx platform, a digital PCR system intended for clinical diagnostics. As the inaugural partner, GENCURIX will develop multiplex oncology assays targeting both tissue and liquid biopsies. The partnership aims to broaden the adoption of the QIAcuityDx Four platform, offering clinical diagnostic laboratories a wide range of oncology assays. This strategic alliance is expected to expand GENCURIX's diagnostic technologies into the global market, leveraging QIAGEN's platform for precision cancer diagnostics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250618798245) on June 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544900251"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544900251\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2544900251?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544900251","market":"nz","top_or_hot":-1,"title":"QIAGEN Partners with GENCURIX to Develop Multiplex Oncology Assays for QIAcuityDx Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QIAGEN Partners with GENCURIX to Develop Multiplex Oncology Assays for QIAcuityDx Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QIAGEN has announced a new partnership with GENCURIX, marking the launch of the QIAcuityDx Partnering Program. This collaboration focuses on developing oncology assays for the QIAcuityDx platform, a digital PCR system intended for clinical diagnostics. As the inaugural partner, GENCURIX will develop multiplex oncology assays targeting both tissue and liquid biopsies. The partnership aims to broaden the adoption of the QIAcuityDx Four platform, offering clinical diagnostic laboratories a wide range of oncology assays. This strategic alliance is expected to expand GENCURIX's diagnostic technologies into the global market, leveraging QIAGEN's platform for precision cancer diagnostics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250618798245) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QIAGEN Partners with GENCURIX to Develop Multiplex Oncology Assays for QIAcuityDx Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQIAGEN Partners with GENCURIX to Develop Multiplex Oncology Assays for QIAcuityDx Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-19 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QIAGEN Partners with GENCURIX to Develop Multiplex Oncology Assays for QIAcuityDx Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QIAGEN has announced a new partnership with GENCURIX, marking the launch of the QIAcuityDx Partnering Program. This collaboration focuses on developing oncology assays for the QIAcuityDx platform, a digital PCR system intended for clinical diagnostics. As the inaugural partner, GENCURIX will develop multiplex oncology assays targeting both tissue and liquid biopsies. The partnership aims to broaden the adoption of the QIAcuityDx Four platform, offering clinical diagnostic laboratories a wide range of oncology assays. This strategic alliance is expected to expand GENCURIX's diagnostic technologies into the global market, leveraging QIAGEN's platform for precision cancer diagnostics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250618798245) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125909247.SGD","symbol_name":"Natixis Thematics Meta H-R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL5014nN:1","article_id":"2544900251","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544900251","pubTimestamp":1750277132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"QIAGEN has announced a new partnership with GENCURIX, marking the launch of the QIAcuityDx Partnering Program. This collaboration focuses on developing oncology assays for the QIAcuityDx platform, a digital PCR system intended for clinical diagnostics. As the inaugural partner, GENCURIX will develop multiplex oncology assays targeting both tissue and liquid biopsies. The partnership aims to broaden the adoption of the QIAcuityDx Four platform, offering clinical diagnostic laboratories a wide range of oncology assays. This strategic alliance is expected to expand GENCURIX's diagnostic technologies into the global market, leveraging QIAGEN's platform for precision cancer diagnostics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4121":"生命科学工具和服务","QGEN":"快而精医药"},"translate_title":"QIAGEN与GENCURIX合作为QIAcuityDx平台开发多重肿瘤检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"QIAGEN Partners with GENCURIX to Develop Multiplex Oncology Assays for QIAcuityDx Platform\n    \n\n        QIAGEN has announced a new partnership with GENCURIX, marking the launch of the QIAcuityDx Partnering Program. This collaboration focuses on developing oncology assays for the QIAcuityDx platform, a digital PCR system intended for clinical diagnostics. As the inaugural partner, GENCURIX will develop multiplex oncology assays targeting both tissue and liquid biopsies. The partnership aims to broaden the adoption of the QIAcuityDx Four platform, offering clinical diagnostic laboratories a wide range of oncology assays. This strategic alliance is expected to expand GENCURIX's diagnostic technologies into the global market, leveraging QIAGEN's platform for precision cancer diagnostics.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20250618798245) on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}